Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bcli · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Brainstorm Cell Therapeutics Inc. (BCLI) measures how much investors pay for each dollar of the company's trailing earnings. BCLI's current PE ratio of N/A is calculated by dividing its stock price of $0.80 by its TTM earnings per share of -$0.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Brainstorm Cell Therapeutics Inc.You BCLI | $9M | N/A | — | -$0.87 |
 Acurx Pharmaceuticals, Inc. ACXP | $3M | N/A | — | -$5.31 |
 Adial Pharmaceuticals, Inc. ADIL | $2M | N/A | — | -$11.93 |
 Addex Therapeutics Ltd ADXN | $4M | N/A | — | -$7.20 |
 BioCardia, Inc. BCDA | $5M | N/A | — | -$1.23 |
 Cardio Diagnostics Holdings, Inc. CDIO | $4M | N/A | — | -$3.71 |
 HCW Biologics Inc. HCWB | $3M | N/A | — | -$3.79 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.11 | — | |
2024-12-31 FY2024 | 1.04x | $2.19 | — | |
2023-12-31 FY2023 | — | $-4.48 | — | |
2022-12-31 FY2022 | — | $-9.93 | — | |
2021-12-31 FY2021 | — | $-10.09 | — | |
2020-12-31 FY2020 | — | $-14.09 | — | |
2019-12-31 FY2019 | — | $-13.64 | — | |
2018-12-31 FY2018 | — | $-10.05 | — | |
2017-12-31 FY2017 | — | $-3.92 | — | |
2016-12-31 FY2016 | — | $-4.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Brainstorm Cell Therapeutics Inc. (BCLI) measures how much investors pay for each dollar of the company's trailing earnings. BCLI's current PE ratio of N/A is calculated by dividing its stock price of $0.80 by its TTM earnings per share of -$0.87.
Frequently asked questions
BCLI pe ratio · 6 questionsBCLI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.80 and TTM EPS of -$0.87. Data sourced from Financial Modeling Prep via BCLI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Brainstorm Cell Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09